cystic fibrosis transmembrane conductance regulator (505-511) has been researched along with tobramycin in 1 studies
| Studies (cystic fibrosis transmembrane conductance regulator (505-511)) | Trials (cystic fibrosis transmembrane conductance regulator (505-511)) | Recent Studies (post-2010) (cystic fibrosis transmembrane conductance regulator (505-511)) | Studies (tobramycin) | Trials (tobramycin) | Recent Studies (post-2010) (tobramycin) |
|---|---|---|---|---|---|
| 17 | 1 | 3 | 4,902 | 629 | 1,205 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borowitz, D; Cimino, M; Simon, D | 1 |
1 other study(ies) available for cystic fibrosis transmembrane conductance regulator (505-511) and tobramycin
| Article | Year |
|---|---|
Normal volume of distribution of tobramycin in a mother and daughter with a CFTR splice mutation (1717 - 1G --> A).
Topics: Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Mutation; Peptide Fragments; Tobramycin | 2002 |